Description

7-[(3R)-3-[(n-Acetyl)Amino]-1-Oxo-4-(2,4,5-Trifluorophenyl)Butyl]-5,6,7,8-Tetrahydro-3-(Trifluoromethyl)-1,2,4-Triazolo[4,3-A]Pyrazine is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound is of critical importance for its role as a key building block in the synthesis of novel, small-molecule therapeutics. It is primarily required by pharmaceutical R&D and manufacturing organizations engaged in developing innovative drug candidates, particularly in metabolic and cardiovascular disease research.

Application

• Pharmaceutical Intermediate: A crucial precursor in the multi-step synthesis of active pharmaceutical ingredients (APIs) for clinical development.
• Protease Inhibitor Research: Serves as a core scaffold for designing and testing novel protease inhibitors due to its specific stereochemistry and functional groups.
• Metabolic Disease Drug Discovery: Used in medicinal chemistry programs targeting enzymes and receptors involved in metabolic disorders.
• Cardiovascular Therapeutic Development: Employed as a building block for candidates aimed at cardiovascular targets.
• Pre-clinical & Clinical Trial Material: Supplied under controlled conditions for the production of materials required for non-clinical studies and early-phase clinical trials.
• Process Chemistry & Scale-Up: Used by process development teams to optimize synthetic routes from laboratory to pilot and commercial scale.
• Reference Standard: High-purity grades are suitable for use as analytical reference standards in quality control laboratories.

Basic Information

Product Name	7-[(3R)-3-[(n-Acetyl)Amino]-1-Oxo-4-(2,4,5-Trifluorophenyl)Butyl]-5,6,7,8-Tetrahydro-3-(Trifluoromethyl)-1,2,4-Triazolo[4,3-A]Pyrazine
CAS No.	1379666-94-0
Molecular Formula	C19H18F6N6O2
Molecular Weight	476.38 g/mol
Synonyms	(3R)-3-Acetamido-1-[4-(2,4,5-trifluorophenyl)-2-oxobutyl]-5-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine; 7-[(3R)-3-(Acetylamino)-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine; 1379666-94-0; UNII-8X6S6Z5Q5H; 8X6S6Z5Q5H; BDBM50166657; AKOS025147324; ZINC000253899996
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency for critical R&D and scale-up work. Quality is verified through a comprehensive suite of analytical techniques including HPLC, NMR, and MS. A Certificate of Analysis (COA) detailing purity, identity, and impurity profiles is provided with each shipment. We support development under GMP-like conditions where required for pre-clinical and clinical applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be handled in a dry environment to prevent degradation. For long-term storage, consider desiccated conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Retention time corresponds to reference standard
Identification (NMR)	Spectrum consistent with structure
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Specific Rotation	Contact for details

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.